Description
Nuclear Matrix Protein 22 (NMP22) Rapid Test
The NMP22 Rapid Test is an in vitro chromatographic immunoassay intended for the qualitative detection of Nuclear Mitotic Apparatus Protein (NUMA), a key component of nuclear matrix proteins, in human urine. This test is designed to aid in the evaluation of individuals with risk factors or symptoms associated with bladder cancer, as well as those with a previous history of the disease.
Supportive Screening Tool for Bladder Cancer
NMP22 is a biomarker often elevated in the urine of patients with bladder cancer. The rapid test allows point-of-care detection to assist physicians in making timely decisions about further diagnostic steps.
Quick and Convenient Detection
This test delivers results in minutes using a urine sample. While it provides a preliminary result, it should always be followed by clinical evaluation and confirmation with additional diagnostic procedures.
Key Benefits
- Qualitative detection of NMP22 in urine
- Useful for individuals with bladder cancer risk or history
- Simple cassette format for point-of-care testing
- Cut-off value: 10 U/mL
- No special storage required (2–30°C)
Specifications
| Specification | Details |
|---|---|
| Specimen | Urine |
| Cut-off Value | 10 U/mL |
| Format | Cassette |
| Storage | 2–30°C |
| Shelf Life | 24 months from the date of manufacture |
Ordering Information
| Product Description | Specimen | Catalog No. | Format | Cut-off Value | Kit Size |
|---|---|---|---|---|---|
| Nuclear Matrix Protein 22 Test | Urine | GENMP22-102a | Cassette | 10 U/mL | 25 Tests/Kit |
